CHIMERIC THERAPEUTICS LIMITED — Investor Relations & Filings

Chimeric Therapeutics Limited is a clinical-stage cell therapy company focused on the development and commercialization of innovative oncology treatments. The company specializes in chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell therapies designed to target solid tumors and hematologic malignancies. Its lead candidate, CHM 1101 (CLTX CAR T), is a first-in-class therapy utilizing chlorotoxin to target glioblastoma. Additionally, the company is developing CHM 2101, a CDH17-targeted CAR T-cell therapy for gastrointestinal cancers, and the CORE-NK platform, which provides a foundation for off-the-shelf NK cell therapies. By leveraging advanced cellular engineering, Chimeric Therapeutics aims to address significant unmet needs in cancer care through precision medicine and novel therapeutic platforms.